Carnosine

What is Carnosine?#

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide found at high concentrations in skeletal muscle, cardiac muscle, and brain tissue. It was first discovered in 1900 by Russian chemist Vladimir Gulevich and consists of beta-alanine bonded to L-histidine through a peptide bond.

In human skeletal muscle, carnosine is present at concentrations of 17-25 mmol/kg dry weight, making it one of the most abundant small molecules in muscle tissue. Muscle carnosine concentrations are higher in type II (fast-twitch) fibers compared to type I (slow-twitch) fibers, and are generally higher in males than females.

Carnosine is synthesized intracellularly by the enzyme carnosine synthase and degraded by carnosinase enzymes. Serum carnosinase (CN1) is particularly active in humans, which rapidly hydrolyzes circulating carnosine back into its constituent amino acids. This enzymatic degradation is a key pharmacological consideration for oral supplementation.

Mechanism of Action#

Carnosine exerts its biological effects through multiple mechanisms:

pH Buffering#

The imidazole ring of histidine in carnosine has a pKa of 6.83, which is within the physiological range of pH changes during exercise. This makes carnosine an effective intracellular buffer, contributing approximately 10-20% of total buffering capacity in skeletal muscle. During high-intensity exercise, carnosine helps counteract the accumulation of hydrogen ions from anaerobic metabolism.

Anti-Glycation#

Carnosine inhibits the formation of advanced glycation end products (AGEs) through multiple pathways. It can react with reactive carbonyl species (methylglyoxal, glyoxal) before they can modify proteins, a process termed "carnosinylation." It may also prevent early Maillard reaction products from progressing to AGEs and can potentially reverse some already-formed glycated protein modifications.

Antioxidant Activity#

Carnosine scavenges reactive oxygen species (ROS) and reactive nitrogen species. It also quenches alpha-beta unsaturated aldehydes such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) that are formed during lipid peroxidation of cell membrane fatty acids.

Metal Ion Chelation#

Carnosine chelates divalent metal ions including zinc, copper, and iron, which can reduce metal-catalyzed oxidative damage and may influence metalloenzyme activity.

Research Overview#

Carnosine research spans over a century, with modern clinical investigation focusing on three primary areas:

1. Glycemic control: Randomized controlled trials have demonstrated that 1-2 g/day oral carnosine improves glucose tolerance in adults with prediabetes and type 2 diabetes, with reductions in fasting glucose, HbA1c, and AGE markers.

2. Cognitive function: A systematic review with meta-analysis found that 1 g/day carnosine/anserine supplementation for 12 weeks improved global cognitive function in elderly subjects and patients with mild cognitive impairment.

3. Cataract management: N-acetylcarnosine (NAC) eye drops have been studied as a topical anti-cataract agent, though a Cochrane review found insufficient evidence to confirm efficacy.

Additional preclinical research has investigated carnosine's potential in neuroprotection, wound healing, and cardiovascular health.

Important Considerations#

Carnosine is a dietary supplement, not an approved pharmaceutical. While it has a favorable safety profile at doses up to 2 g/day, several factors should be considered:

• Serum carnosinase: Human CN1 rapidly degrades circulating carnosine, potentially limiting bioavailability. This is a uniquely human challenge, as most animal models have lower carnosinase activity.
• Beta-alanine alternative: For the specific goal of increasing muscle carnosine levels, beta-alanine supplementation may be more efficient, as beta-alanine is the rate-limiting substrate for carnosine synthesis and is not degraded by carnosinase.
• Evidence quality: While promising, the clinical trial evidence base remains limited in size. Most trials are small (30-60 participants) and of moderate duration (12-14 weeks).
• Individual variation: Genetic polymorphisms in the CN1 gene affect carnosinase activity, which may influence individual response to supplementation.

Key Research Findings#

L-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes, published in Nutrition Research (Houjeghani S et al., 2018; PMID: 29420997):

• The study showed significant reduction in serum carboxymethyl lysine of 91.8 ng/mL

The therapeutic potential of carnosine/anserine supplementation against cognitive decline: A systematic review with meta-analysis, published in Biomedicines (Caruso G et al., 2021; PMID: 33806459):

• The study showed PRISMA compliant review of 516 initially identified studies, 5 included

Efficacy of N-acetylcarnosine in the treatment of cataracts, published in Drugs in R&D (Babizhayev MA et al., 2002; PMID: 12001824):

• The study demonstrated of NAC treated eyes showed improved best corrected visual acuity of 90% at 6 months
• The study demonstrated showed improvement of 88.9% in glare sensitivity at 6 months
• The study showed randomized placebo controlled study of 1% N acetylcarnosine eye drops in 49 subjects with age related cataracts over 6 and 24 months. Reported improvements in visual acuity and glare sensitivity. However, subsequent Cochrane review questioned the quality of evidence.

Related Reading#

• Carnosine research studies and evidence
• Carnosine dosing protocols
• Carnosine side effects profile
• GHK-Cu research guide
• Klotho Peptides research guide